Davita Inc vs Hormel Foods Corp — how do they compare? Davita Inc trades at $230.55 (market cap $14.92B), while Hormel Foods Corp trades at $24.8 (market cap $13.65B). The key difference: Davita Inc and Hormel Foods Corp are close in size by market cap, and Hormel Foods Corp pays a 4.72% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | HRL | |
|---|---|---|
Market Cap | $14.92B | $13.65B |
Sector | Health | Consumer Staples |
52-Week High | $235.71 | $29.91 |
52-Week Low | $103.87 | $19.74 |
Enterprise Value | $27.47B | $15.65B |
Dividend Yield | — | 4.72% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Hormel Foods (HRL) trades at $24.46, down 1.11% on the day, with a neutral technical outlook and mixed analyst sentiment. The company has beaten earnings estimates for three consecutive quarters, though net income margin has compressed to 3.82% in 2025 from 6.75% in 2024. Recent strategic moves include the sale of its Brazilian Ceratti operations to focus on higher-growth markets, while maintaining its Dividend King status with 60 consecutive years of dividend increases.
The stock presents a value opportunity with a P/E of 28.78 and consensus price target of $26.33 (7.6% upside), but faces margin pressure from input cost inflation and competitive headwinds. The dividend yield of approximately 4.7% provides income support, though earnings stabilization remains key for sustained recovery from multi-year lows.
Trailing returns across standard periods
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →